RSI-MRI is an imaging biomarker that differentiates aggressive prostate cancer

Prognostic biomarker for responsiveness to Anti-CD47 immunotherapy

A new, non-invasive way to diagnose mesothelioma

Next generation cytotoxics and cytostatics

Frost Biologic was founded in 2007 as a spinoff of Brigham Young University (BYU) and was originally based on using phenotypic screening to identify small molecules that alter cellular behaviors associated with cancer progression. Since then, Frost has developed robust chemistry and preclinical research capabilities. Molecules derived from this screening approach are thoroughly optimized and put through a rigorous preclinical development program that is designed to yield the best possible clinical candidates. While Frost is ready to partner or license its programs once a clinical candidate has been nominated and when preclinical proof of concept is complete, Frost also initiates GLP studies and Phase I clinical trials as soon as its programs are ready. 

by
15 hours ago

Endo-rectal diagnostic tool for improved detection of prostate cancer

Current methods to diagnose prostate cancer (lat. Carcinoma) involve a combination of histologic examinations, prostate antigen testing, and digital rectal examinations. Histological examinations require invasive tissue biopsies, while prostate antigen testing and rectal examination are limited by detection and localization accuracy. As a result, these diagnostic methods to identify prostate cancer lack sensitivity, specificity, and convenience. There are currently, no available methods for accurately and non-invasively distinguishing malignant tumors from benign tissue in the prostate. Therefore, scientists including Andreas Helmut Hielscher, Hyun Keol Kim, Jong Hwan Michael Lee, and Emerson Lim at the Columbia University developed a technology that implements endo-rectal diffuse optical tomography (DOT) imaging to assess tumor localization, vascularity, and architecture for a more accurate detection and diagnosis of prostate cancer.

by
15 hours ago

A new biomarker for breast cancer

An oncogene discovered by the scientific group at the National University of Singapore (NUS) could be used as a biomarker for the early detection and prognosis of breast cancer (lat. Carcinoma). The patent has been licensed to Singapore biomedical diagnostic company Restalyst Pte Ltd to be commercialized into a test kit. The WBP2 gene, uncovered in 2011 by Assistant Professor Lim Yoon Pin of NUS Biochemistry and his team, has been determined to cause the rapid proliferation of breast cancer cells. In the current study, researchers found that the level of this oncogene was elevated in up to 90% of patients with breast cancer. Even precancerous tissue showed significantly raised level of the gene compared to normal tissues. In other words, this oncogene is an accurate biomarker for the early detection of breast cancer.

by
15 hours ago

Next Wave of Medicines in Neuroscience and Immuno-Oncology

Apitope provides treatments to autoimmune diseases

Miniature 'bleeding' device eases study of clotting disorders

Developing next-generation hemophilia products for patients in need

The treatment of hemophilia (lat. Haemophilia, also spelt as hemophilia) was developed by Catalyst Biosciences. The company is a clinical-stage biotech company focused on the treatment of hemophilia. The company used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Most currently approved medicines for hemophilia are injected into a patient’s veins (intravenous, or IV) – at Catalyst, scientists believe that a clotting factor that could be injected just under the skin (subcutaneous, or SQ) would simplify the treatment, and enhance the lives of individuals with hemophilia.

by
15 hours ago

Topoisomerase II inhibition for glioma treatment

Gliomas are brain tumours with remarkably heterogeneous gene expression patterns and very poor response to chemotherapy. Although drugs targeting specific oncogenic pathways have been tested for treatment of gliomas, effective treatment remains elusive as tumours can easily overcome monogenic blockades and develop resistance. As such, there is a need for therapeutic strategies that target multiple oncogenic pathways simultaneously in order to provide an effective treatment of gliomas. Therefore, scientists, including Edgar F Gonzalez Buendia, Eric Feldstein, Aayushi Mahajan, and Adam Sonabend from the Northwestern Medical Group, who led the research at the Columbia University, developed a novel technology that identifies topoisomerase II inhibition as a potential treatment strategy for a subset of gliomas with MYC and PDGFRA overexpression. The method offers a reliable and simple biomarker for identifying patients that will benefit from the therapy.

by
15 hours ago

Biomarker for measuring immunotherapy response

The new technology to measure patient response to immunotherapy was developed by Bio-Rad Laboratories, Inc. New research demonstrating the clinical potential of Bio-Rad's Droplet Digital PCR (ddPCR). This technology was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Monitoring patient response in immunotherapies is essential to optimizing treatments in the clinic. Studies have shown that circulating tumor DNA (ctDNA) can provide an early indicator of whether or not these treatments are working. Droplet Digital PCR technology is a digital PCR method utilizing a water-oil emulsion droplet system. Droplets are formed in a water-oil emulsion to form the partitions that separate the template DNA molecules. The droplets serve essentially the same function as individual test tubes or wells in a plate in which the PCR reaction takes place, albeit in a much smaller format. The massive sample partitioning is a key aspect of the ddPCR technique.

by
15 hours ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM